ArticleFrontiers in immunology2025

FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation.

Sirui Hang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.